ArchPoint Investors’s Astria Therapeutics ATXS Stock Holding History

ArchPoint Investors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,331	Closed	-$220K	–	57
2022 Q3	$220K	Sell	24,331 -1,416	-5%	-$9.49K	0.09%	54
2022 Q2	$77K	Hold	25,747	–	–	0.03%	56
2022 Q1	$173K	Hold	25,747	–	–	0.06%	56
2021 Q4	$139K	Sell	25,747 -2,500	-9%	-$16.4K	0.04%	65
2021 Q3	$250K	Buy	28,247 +480	+2%	+$4.6K	0.07%	86
2021 Q2	$352K	Buy	27,767 +629	+2%	+$8.17K	0.12%	42
2021 Q1	$471K	Buy	+27,138	New	+$490K	0.13%	72

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ArchPoint Investors's ATXS Position: Q4 2022 in Review

ArchPoint Investors sold out of Astria Therapeutics (ATXS) in Q4 2022, closing a stake of 24,331 shares — an estimated $220K sold.

ArchPoint Investors first reported a position in ATXS in Q1 2021 and held it in 7 quarters. The position peaked at $471K in Q1 2021. 61 funds tracked by Wall St. Rank hold ATXS as of Q4 2022.

ArchPoint Investors reported no remaining Astria Therapeutics position as of Q4 2022 after selling out during the quarter.
ArchPoint Investors sold 24,331 Astria Therapeutics shares in Q4 2022, an estimated $220K.
ArchPoint Investors first reported a position in Astria Therapeutics in Q1 2021 and held it in 7 quarters.
ArchPoint Investors's Astria Therapeutics position peaked at $471K in Q1 2021.
61 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2022.

Based on ArchPoint Investors's 13F filing for Q4 2022, filed 13 Feb 2023.